Document Type

Article

Publication Date

1-1-2023

Keywords

JMG, JCA, Humans, Cytokine Release Syndrome, Drug-Related Side Effects and Adverse Reactions, Drug Discovery, Immune Checkpoint Inhibitors, Immunotherapy, Neoplasms

JAX Source

Front Immunol. 2023;14:1190379

ISSN

1664-3224

PMID

37304291

DOI

https://doi.org/10.3389/fimmu.2023.1190379

Grant

This work was supported by The Jackson Laboratory.

Abstract

Cancer is the leading cause of death worldwide. Cancer immunotherapy involves reinvigorating the patient's own immune system to fight against cancer. While novel approaches like Chimeric Antigen Receptor (CAR) T cells, bispecific T cell engagers, and immune checkpoint inhibitors have shown promising efficacy, Cytokine Release Syndrome (CRS) is a serious adverse effect and remains a major concern. CRS is a phenomenon of immune hyperactivation that results in excessive cytokine secretion, and if left unchecked, it may lead to multi-organ failure and death. Here we review the pathophysiology of CRS, its occurrence and management in the context of cancer immunotherapy, and the screening approaches that can be used to assess CRS and de-risk drug discovery earlier in the clinical setting with more predictive pre-clinical data. Furthermore, the review also sheds light on the potential immunotherapeutic approaches that can be used to overcome CRS associated with T cell activation.

Comments

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Download

Share

COinS